Gwenn Hansen Sells 3,690 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $20.01 on Friday. The business has a 50 day simple moving average of $20.14 and a 200 day simple moving average of $22.40. Nurix Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on NRIX shares. UBS Group began coverage on Nurix Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target for the company. Needham & Company LLC dropped their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday. BTIG Research assumed coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus upped their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada increased their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $30.71.

Institutional Investors Weigh In On Nurix Therapeutics

Several large investors have recently made changes to their positions in the company. Amalgamated Bank boosted its position in shares of Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after buying an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. Quest Partners LLC boosted its position in Nurix Therapeutics by 21.3% during the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after acquiring an additional 1,312 shares during the period. Teachers Retirement System of The State of Kentucky grew its stake in shares of Nurix Therapeutics by 8.4% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company’s stock worth $675,000 after purchasing an additional 2,329 shares in the last quarter. Finally, Quarry LP increased its holdings in shares of Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after purchasing an additional 2,435 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.